{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:48:52Z","timestamp":1787060932862,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11845-017-1689-6","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T03:37:41Z","timestamp":1508211461000},"page":"343-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Surgical management of splenic marginal zone lymphoma"],"prefix":"10.1007","volume":"187","author":[{"given":"N. D.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. N.","family":"L\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"crossref","unstructured":"De Pasquale A, Paterlini P, Di Francesco A,\u00a0Vecchio L,\u00a0Quaglino D\u00a0(1986) Follicular lymphomas with predominant splenic involvement: report of two cases. Tumori 72(1):109\u2013115","DOI":"10.1177\/030089168607200117"},{"key":"1689_CR2","unstructured":"Swerdlow SH,\u00a0Campo E, Piler SA et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2. IARC Press, Lyons"},{"issue":"17","key":"1689_CR3","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","volume":"127","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Rossi D, Paulli M (2016) Splenic marginal zone lymphoma: from genetics to management. Blood 127(17):2072\u20132081","journal-title":"Blood"},{"key":"1689_CR4","doi-asserted-by":"crossref","unstructured":"Kalpadakis C, Pangalis GA,\u00a0Angelopoulou MK et al (2017) Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol 30(1\u20132):139\u2013148","DOI":"10.1016\/j.beha.2016.07.004"},{"key":"1689_CR5","doi-asserted-by":"crossref","unstructured":"Matutes E, Oscier D,\u00a0Montalban C et al (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22(3):487\u2013495","DOI":"10.1038\/sj.leu.2405068"},{"key":"1689_CR6","doi-asserted-by":"crossref","unstructured":"Liu L,\u00a0Wang H,\u00a0Chen Y et al (2013) Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leuk Lymphoma 54(7):1380\u20131386","DOI":"10.3109\/10428194.2012.743655"},{"issue":"2","key":"1689_CR7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/157488410791110751","volume":"5","author":"L Arcaini","year":"2010","unstructured":"Arcaini L, Bruno R (2010) Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. Curr Clin Pharmacol 5(2):74\u201381","journal-title":"Curr Clin Pharmacol"},{"key":"1689_CR8","doi-asserted-by":"crossref","unstructured":"Arcaini L, Paulli M,\u00a0Boveri E et al (2004) Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 100(1):107\u2013115","DOI":"10.1002\/cncr.11893"},{"issue":"12","key":"1689_CR9","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/jcp.2007.051870","volume":"60","author":"DS Viswanatha","year":"2007","unstructured":"Viswanatha DS, Dogan A (2007) Hepatitis C virus and lymphoma. J Clin Pathol 60(12):1378\u20131383","journal-title":"J Clin Pathol"},{"key":"1689_CR10","doi-asserted-by":"crossref","unstructured":"Joshi M,\u00a0Sheikh H,\u00a0Abbi K et al (2012) Marginal zone lymphoma: old, new, targeted, and epigenetic therapies. Ther Adv Hematol 3(5):275\u2013290","DOI":"10.1177\/2040620712453595"},{"key":"1689_CR11","doi-asserted-by":"crossref","unstructured":"Arcaini L,\u00a0Rossi D,\u00a0Lucioni M et al (2015) The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica 100(2):246\u2013252","DOI":"10.3324\/haematol.2014.116855"},{"issue":"4","key":"1689_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pathog.2015.07.001","volume":"2","author":"M-Q Du","year":"2015","unstructured":"Du M-Q (2015) Pathogenesis of splenic marginal zone lymphoma. Pathogenesis 2(4):11\u201320","journal-title":"Pathogenesis"},{"key":"1689_CR13","doi-asserted-by":"crossref","unstructured":"Arcaini L,\u00a0Lazzarino M,\u00a0Colombo N et al (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107(12):4643\u20134649","DOI":"10.1182\/blood-2005-11-4659"},{"issue":"3","key":"1689_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","volume":"119","author":"AJ Olszewski","year":"2013","unstructured":"Olszewski AJ, Castillo JJ (2013) Survival of patients with marginal zone lymphoma. Cancer 119(3):629\u2013638","journal-title":"Cancer"},{"key":"1689_CR15","doi-asserted-by":"crossref","unstructured":"Montalban C,\u00a0Abraira V,\u00a0Arcaini L et al (2011) Stratification approach for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH and extrahilar lymphadenopathy: the HPLL\/ABC system. Blood 118(21):1538","DOI":"10.1182\/blood.V118.21.1583.1583"},{"key":"1689_CR16","doi-asserted-by":"crossref","unstructured":"Montalban C,\u00a0Abraira V,\u00a0Arcaini L et al (2014) Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 55(4):929\u2013931","DOI":"10.3109\/10428194.2013.818143"},{"key":"1689_CR17","doi-asserted-by":"crossref","unstructured":"Kalpadakis C,\u00a0Pangalis GA,\u00a0Angelopoulou MK et al (2014) Validation of the simplified prognostic score for splenic marginal zone lymphoma of the splenic marginal zone lymphoma working group. Leuk Lymphoma 55(11):2640\u20132642","DOI":"10.3109\/10428194.2014.897703"},{"key":"1689_CR18","unstructured":"Bennett M,\u00a0Schechter GP\u00a0(2010) Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy. Br J Haematol 149:45"},{"key":"1689_CR19","doi-asserted-by":"crossref","unstructured":"Kalpadakis C,\u00a0Pangalis GA,\u00a0Vassilakopoulos TP et al (2014) Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? Leuk Lymphoma 55(7):1463\u20131470","DOI":"10.3109\/10428194.2013.845884"},{"key":"1689_CR20","doi-asserted-by":"crossref","unstructured":"Else M,\u00a0Mar\u00edn-Niebla A,\u00a0de la Cruz F et al (2012) Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 159(3):322\u2013328","DOI":"10.1111\/bjh.12036"},{"issue":"2","key":"1689_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205\u2013213","journal-title":"Ann Surg"},{"key":"1689_CR22","doi-asserted-by":"crossref","unstructured":"Ponzoni M,\u00a0Kanellis G,\u00a0Pouliou E et al (2012) Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? Am J Surg Pathol 36(11):1609\u20131618","DOI":"10.1097\/PAS.0b013e318271243d"},{"key":"1689_CR23","doi-asserted-by":"crossref","unstructured":"Thieblemont C,\u00a0Nasser V,\u00a0Felman P et al (2004) Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103(7):2727\u20132737","DOI":"10.1182\/blood-2003-06-2160"},{"key":"1689_CR24","unstructured":"Sun Q,\u00a0\u00a0Zhang PH,\u00a0Liu EB et al (2013) Clinicopathologic features and differential diagnosis of splenic B-cell marginal zone lymphoma involving bone marrow. Zhonghua Bing Li Xue Za Zhi 42(4):234\u2013238"},{"key":"1689_CR25","unstructured":"Gazzola A,\u00a0Sabattini E,\u00a0Mannu C et al (2011) Partial nodal involvement by marginal zone lymphoma. Use of IGK gene rearrangement analysis in diagnostic work-up. Pathologica 103(1):14\u201318"},{"key":"1689_CR26","doi-asserted-by":"crossref","unstructured":"Munari E,\u00a0Rinaldi M,\u00a0Ambrosetti A et al (2012) Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. Virchows Arch 461(6):677\u2013685","DOI":"10.1007\/s00428-012-1322-z"},{"key":"1689_CR27","unstructured":"Khodzhibekova MM,\u00a0Tiutin LA,\u00a0Kostenikov NA et al (2015) 18F\u2013FDG positron emission tomography in the diagnosis and staging of marginal zone non-Hodgkin lymphomas. Vestn Rentgenol Radiol 1:16\u201321"},{"key":"1689_CR28","doi-asserted-by":"crossref","unstructured":"Romano C,\u00a0Sellitto A,\u00a0Chiurazzi F et al (2015) Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia. Int J Hematol 101(1):67\u201374","DOI":"10.1007\/s12185-014-1703-y"},{"key":"1689_CR29","doi-asserted-by":"crossref","unstructured":"Baseggio L,\u00a0Traverse-Glehen A,\u00a0Petinataud F\u00a0et al (2010) CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 95(4):604\u2013612","DOI":"10.3324\/haematol.2009.011049"},{"key":"1689_CR30","unstructured":"Savilo E,\u00a0Campo E,\u00a0Mollejo M et al (1998) Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol 11(7):601\u2013606"},{"issue":"2","key":"1689_CR31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11864-007-0026-0","volume":"8","author":"E Matutes","year":"2007","unstructured":"Matutes E (2007) Splenic marginal zone lymphoma with and without villous lymphocytes. Curr Treat Options in Oncol 8(2):109\u2013116","journal-title":"Curr Treat Options in Oncol"},{"key":"1689_CR32","doi-asserted-by":"crossref","unstructured":"Gutierrez-Civicos R,\u00a0Hurtado AM,\u00a0Torres-Moreno D et al (2017) Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. Pharmacogenet Genomics 27(2):70\u201377","DOI":"10.1097\/FPC.0000000000000262"},{"issue":"2","key":"1689_CR33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","volume":"47","author":"M Bennett","year":"2010","unstructured":"Bennett M, Schechter GP (2010) Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 47(2):143\u2013147","journal-title":"Semin Hematol"},{"key":"1689_CR34","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM,\u00a0Catovsky D,\u00a0Schlette E et al (2006) Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125\u2013135","DOI":"10.1002\/cncr.21931"},{"key":"1689_CR35","doi-asserted-by":"crossref","unstructured":"Perrone S,\u00a0D\u2019Elia GM,\u00a0Annechini G et al (2016) Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leuk Res 44:53\u201360","DOI":"10.1016\/j.leukres.2016.03.005"},{"key":"1689_CR36","doi-asserted-by":"crossref","unstructured":"Lenglet J,\u00a0Traull\u00e9 C,\u00a0Mounier N et al (2014) Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 55(8):1854\u20131860","DOI":"10.3109\/10428194.2013.861067"},{"key":"1689_CR37","doi-asserted-by":"crossref","unstructured":"Thieblemont C,\u00a0Felman P,\u00a0Berger F et al (2002) Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 3(1):41\u201347","DOI":"10.3816\/CLM.2002.n.010"},{"key":"1689_CR38","doi-asserted-by":"crossref","unstructured":"Xing KH,\u00a0Kahlon A,\u00a0Skinnider BF et al (2015) Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol 169(4):520\u2013527","DOI":"10.1111\/bjh.13320"},{"issue":"12","key":"1689_CR39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1046\/j.1198-743x.2001.00355.x","volume":"7","author":"RN Davidson","year":"2001","unstructured":"Davidson RN, Wall RA (2001) Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 7(12):657\u2013660","journal-title":"Clin Microbiol Infect"},{"key":"1689_CR40","doi-asserted-by":"crossref","unstructured":"Schreiber DP,\u00a0Jacobs C,\u00a0Rosenberg SA et al (1985) The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin\u2019s lymphomas. Int J Radiat Oncol Biol Phys 11(1):31\u201336","DOI":"10.1016\/0360-3016(85)90359-1"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-017-1689-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-017-1689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-017-1689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T21:16:03Z","timestamp":1603142163000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-017-1689-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s11845-017-1689-6","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]}}}